XOMA Royalty Corporation Engages in Major Finance Events
EMERYVILLE, Calif. — XOMA Royalty Corporation (NASDAQ: XOMA), a notable player in the biotech royalty sector, has announced significant participation in prominent upcoming financial conferences. The company's Chief Executive Officer, Owen Hughes, and Chief Investment Officer, Brad Sitko, are set to take the stage during the H.C. Wainwright 1st Annual Royalty Company Virtual Conference, scheduled for mid-May this year.
Key Presentations and Topics
At the conference, Mr. Hughes will deliver insights during a fireside chat at 2:30 PM ET, followed by his participation in a panel discussion focusing on the advantages and challenges of the royalty model within the current financing landscape at 4:00 PM ET. Furthermore, Mr. Sitko will engage in a dialog about the evolving role of royalty and technology platforms in relation to development-stage companies during a panel at 5:00 PM ET. These discussions aim to enlighten investors about the complexities and opportunities in biotech financing.
Exciting Future Engagements
In addition to the virtual conference, members of XOMA Royalty's business development team will also attend the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, in New York, NY. This provides yet another platform for XOMA Royalty to showcase its growth strategy and innovative approach within the biotechnology industry.
Understanding XOMA Royalty Corporation's Impact
XOMA Royalty plays a critical role in aiding biotechnology firms in their mission to enhance human health. The company strategically acquires potential future economics associated with various therapeutic candidates, whether they are still in development or already commercialized. This process allows sellers to secure non-dilutive and non-recourse funding, which they can utilize for advancing their internal projects or for broader corporate activities.
With an expansive and continuously growing portfolio, XOMA Royalty represents a unique asset base defined as the rights to receive potential future revenues tied to the progress of underlying therapeutic candidates. This innovative business model allows for a distinct approach to funding in the biotech landscape, aligning with the fiscal needs and commercial goals of partner companies.
Explore More About XOMA Royalty
For those interested in learning more about XOMA Royalty's initiatives and its diverse asset portfolio, additional information can be found on the company's official website. Furthermore, XOMA Royalty is active on social media platforms, making it easier for stakeholders to keep up with the latest news and updates from the company.
Contact Information for Inquiries
XOMA Investor Contact
Juliane Snowden
XOMA Royalty
+1 646-438-9754
juliane.snowden@xoma.com
XOMA Media Contact
Kathy Vincent
KV Consulting & Management
kathy@kathyvincent.com
Frequently Asked Questions
What is XOMA Royalty Corporation?
XOMA Royalty Corporation is a biotech royalty aggregator that focuses on acquiring potential future economics from therapeutic candidates, aiding biotech firms in funding their innovations.
Who will represent XOMA at the upcoming conferences?
The Chief Executive Officer, Owen Hughes, and Chief Investment Officer, Brad Sitko, will represent XOMA Royalty at the H.C. Wainwright conferences.
What topics will be discussed during the conferences?
Discussions will focus on the royalty model in the current financing context and the intersection of development-stage companies with royalty and technology platforms.
When is the H.C. Wainwright 1st Annual Royalty Company Virtual Conference?
The conference is set to take place in mid-May, with specific timings for XOMA's presentations detailed in the announcement.
How can I learn more about XOMA Royalty?
More information about XOMA Royalty can be obtained through their official website and by following them on their LinkedIn page for regular updates.
